Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2008

View Archived Issues

Inhibitors of JAK2 V617F mutation developed at SGX Pharmaceuticals

IMC-3G3 well tolerated in phase I advanced solid tumor study

AVX-13616 active against Gram-positive, vancomycin-resistant pathogens

Snapshots of studies of a new fluoroquinolone, finafloxacin

Pfizer discontinues phase III program for CP-945,598 for weight management

Salvat submits complete response to FDA approvable letter for Cetraxal

AEGR-733 phase II data demonstrates significant lowering of LDL cholesterol

Poniard presents top-line results from phase I oral picoplatin trial

AnaMar raises funds for chronic joint diseases clinical program

Bavarian reports successful safety data from phase II Imvamune study

FDA approves Ranexa for first-line treatment of chronic angina

Repligen initiates phase IIb RG-2417 study in bipolar disorder

Recent Dainippon Sumitomo patent discloses new antiinflammatory agents

Recent Pfizer patent imparts new therapeutic agents for glaucoma

CEM-101 snapshots: Synthesis, preclinical testing, phase I data

ConjuChem presents an update on the clinical development of PC-DAC and PC-Insulin

Canopus granted permission to initiate phase II clinical trial of CB-5300 in HCV

Sanochemia and Avigen terminate licensing agreement for tolperisone for MS

NMRC to develop dengue DNA vaccine formulated with Vical's Vaxfectin

Exelixis and Bristol-Myers extend research agreement for therapies targeted against LXR

Novel agents for liver diseases reported in recent Nisshin patent

BTG licenses novel anticancer compound BGC-945 to Onyx

Phase III study shows Tarceva improves progression-free survival in NSCLC

WuXi PharmaTech collaborates with Pfizer on ADME assays

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...